The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Subscribe To Our Newsletter & Stay Updated
